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EDITORS’ COMMENTDebate Whether Fenestrated Endografts Should be Limited to a Small
Number of Specialized CentersDuring the last decade a relatively small number of centers
worldwide, including Professor Haulon’s, has gained exten-
sive experience treating juxtarenal and suprarenal abdom-
inal aortic aneurysms with fenestrated devices (FEVAR).
These pioneers should be commended for the excellent
outcomes they have achieved and their contributions to
continued device reﬁnement and development. This has
primarily been achieved using Cook’s (Bloomington, IN)
custom-made fenestrated device platform and has resulted
in close collaboration between these expert physicians and
industry. The required surgical skills and the planning and
device manufacturing process has kept this group of expert
physicians relatively small, while others, including Dr
Ricotta, developed parallel techniques including chimneys,
snorkels and surgeon modiﬁed grafts.1
But time are changing with a greater availability of
fenestrated devices from different manufacturers and the
steady removal of the customization process with off-the-
shelf designs. In the spring of 2012, Cook’s Zenith custom
fenestrated device received approval from the Food & Drug
Administration in the United States permitting more
patients to beneﬁt and more surgeons to gain access. The
customization and planning process will permit surgeons
new to this procedure to interact with industry experts and
to receive guidance and training from more experienced
surgeons through proctoring programs provided by the
device manufacturer. Meanwhile the custom fenestrated
device market has expanded to include the Anaconda
fenestrated device2 (Vascutek, Inchinnan, UK).
Major technological advances have been achieved in the
fenestrated arena with preloaded catheters ﬁne tuning the
procedure and the availability of off-the-shelf devices. Both
Cook, with their Pivot or p-branch device,3 and Endologix
(Irvine, CA), with the Ventana device,4 offer devices that,
although not appropriate for all patients, preclude the
customization process. Although this is an obvious advan-
tage, it removes the close link between surgeons and the
device planners and engineers that previously had been so
important in the learning process.
This burgeoning period of increased fenestrated device
availability is similar to the not so distant past when stan-
dard endovascular grafts were becoming more widely
available from more and more manufacturers. At that time,
despite a wide variation in clinical practice, vascular socie-
ties entered the void with practice guidelines and reporting
standards.5,6 According to a recent report 59% of cases
treated between 1999 and 2008 with a standard endovas-
cular device had a maximum aneurysm diameter below therecommended repair threshold of 55 mm, and only 42%
had anatomy that met the instructions-for-use deﬁnition.7
With both the clinical and economic costs higher with
fenestrated devices, uncontrolled and irresponsible diffu-
sion of this technology, without the necessary education
and safeguards, will result in outcomes that do disservice to
surgeons, industry and, most importantly, patients.
As this technology becomes more widely available,
several safeguards are necessary to ensure continued
excellent outcomes. There is currently a lack of major
vascular society guidelines or recommendations regarding
fenestrated repair outside of a recently published UK
consensus document.8 In the absence of randomized
controlled trials comparing open surgery and endovascular
fenestrated repair, speciﬁc guidelines and reporting stan-
dards are needed, perhaps similar to the objective perfor-
mance goals documents that were generated for critical
limb ischemia.9 In addition tracking of outcomes with
registries is necessary to document and report real world
outcomes. These registries may be generated by speciality
societies, similar to the recent British report,10 or by
industry whose best interest is to share the responsibility
and to ensure optimal outcomes with this advanced tech-
nology. The time of greater availability of fenestrated
devices is upon us and our patients will beneﬁt if surgeons
and industry act carefully and responsibly.REFERENCES
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